Fig. 3From: Access to innovative cancer medicines in a middle-income country - the case of MexicoTotal annual quantities of eight essential cancer medicines, procured in the Mexican public sector (SHI institutions and MoH) per insurance scheme (2010–2016). *1000 inhabitants covered per SHI institution and by the MoH/SPS; for abbreviations see Table 1Back to article page